Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

By sjmartinez • July 5, 2024

Clark VC, Strange C, Strnad P, Sanchez AJ, Kwo P, Pereira VM, van Hoek B, Barjaktarevic I, Corsico AG, Pons M, Goldklang M, Gray M, Kuhn B, Vargas HE, Vierling JM, Vuppalanchi R, Brantly M, Kappe N, Chang T, Schluep T, Zhou R, Hamilton J, San Martin J, Loomba R. Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Jul 2:S0016-5085(24)05181-3. doi: 10.1053/j.gastro.2024.06.028. Epub ahead of print. PMID: 38964420.

Tags: AAT, alpha-1 antitrypsin deficiency, Fazirsiran, Liver disease, Publications, Pulmonary, Critical Care & Sleep Medicine, Z-AAT

Stress Trajectory and Hypertension 2 to 7 Years After Delivery: A nuMoM2b-HHS Study

Nuckols VR, Barone Gibbs B, Brewer BC, Gaffey AE, Greaney JL, Patterson F, Greenland P, Saade GR, Grobman WA, Yee LM, Bairey Merz CN, Chung[...]

Incidence and predictors of postoperative recall of propofol injection pain: a prospective observational cohort pilot study

Bellouni G, Clanet M, Touihri K, Delaporte A, Boulos NM, Kim K, Grogan T, Alexander B, Coeckelenbergh S, Joosten A. Incidence and predictors of postoperative[...]

From Insight to Impact: Advancing Learning Health System Capability Through a System-Wide Quality Improvement Symposium

Dermenchyan A, Seiden DS, Bhayani M, Song A, Venkatesan N, Sharma K, Pandrangi K, Han MA. From Insight to Impact: Advancing Learning Health System Capability[...]